



NCCLS

Multi Drug Screening Test (Urine)

Single and multi drug screen test cards for any combination of the following drugs:

AMP/BAR/BZO/COC/THC/MTD/mAMP/MDMA/MOP/OPI/PCP/TCA

(Catalog. No. Varies on Configuration)

A rapid, one step screening test for the simultaneous, qualitative detection of multiple drugs and drug metabolites in human urine.

For healthcare professionals including professionals at point of care sites.

For in vitro diagnostic use only.

**Drugs of Abuse Screening Test
Catalog No. Varies on Configuration (Urine Procedure)**

TABLE OF CONTENTS

| Page Number | Contents |
|--------------------|---|
| 3 | Title |
| 5 | Background <ul style="list-style-type: none">• Summary and Explanation of Test• Principle of the Procedure |
| 10 | Materials |
| 12 | Test Procedure |
| 13 | Interpretation of Results Limitations |
| 14 | Quality Control |
| 15 | Performance Characteristics |
| 24 | References |

**Drugs of Abuse Screening Test
Catalog No. Varies on Configuration (Urine Procedure)**

This procedural bulletin is intended to provide a ready outline reference for performance of the assay. These abbreviated directions are not intended to replace the complete package insert. It is the obligation of every manufacturer of medical devices labeled FOR *in vitro* DIAGNOSTICS USE to provide a complete package insert in accordance with the format and specification recommended by the National Committee for Clinical Laboratory Standards, Villanova, PA 19085; this bulletin is intended for use in conjunction with the Physicians Office Laboratory Procedural Manual, NCCLS Document POL2-T.

Multi Drug Screening Test (Urine)

**Single and multi drug screen test cards for any
combination of the following drugs:**

AMP/BAR/BZO/COC/THC/MTD/mAMP/MDMA/MOP/OPI/PCP/TCA

(Catalog. No. Varies on Configuration)

**A rapid, one step screening test for the simultaneous, qualitative detection
of multiple drugs and drug metabolites in human urine.**

For healthcare professionals including professionals at point of care sites.

For in vitro diagnostic use only.

**Drugs of Abuse Screening Test
Catalog No. Varies on Configuration (Urine Procedure)**

INTENDED USE

The One Step Drug Screen Test Card is a lateral flow chromatographic immunoassay for the qualitative detection of multiple drugs and drug metabolites in urine at the following cut-off concentrations:

| Test | Calibrator | Cut-off |
|--|----------------------------------|-------------|
| Amphetamine (AMP) | D-Amphetamine | 1,000 ng/mL |
| Barbiturates (BAR) | Secobarbital | 300 ng/mL |
| Benzodiazepines (BZO) | Oxazepam | 300 ng/mL |
| Cocaine (COC) | Benzoyllecgonine | 300 ng/mL |
| Marijuana (THC) | 11-nor- ⁹ -THC-9 COOH | 50 ng/mL |
| Methadone (MTD) | Methadone | 300 ng/mL |
| Methamphetamine (mAMP) | D-Methamphetamine | 1,000 ng/mL |
| Methylenedioxyamphetamine (MDMA) Ecstasy | D,L Methylenedioxyamphetamine | 500 ng/mL |
| Morphine (MOP 300) | Morphine | 300 ng/mL |
| Opiates (OPI 2000) | Morphine | 2,000 ng/mL |
| Phencyclidine (PCP) | Phencyclidine | 25 ng/mL |
| Tricyclic Antidepressants (TCA) | Nortriptyline | 1,000 ng/mL |

Configurations of the One Step Multi-Drug Screen Test Card can consist of any combination of the above listed drug analytes. This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

Drugs of Abuse Screening Test
Catalog No. Varies on Configuration (Urine Procedure)

BACKGROUND

Summary and Explanation of Test

The One Step Drug Screen Test Card is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes monoclonal antibodies to selectively detect elevated levels of specific drugs in urine.

AMPHETAMINE (AMP)

Amphetamine is a Schedule II controlled substance available by prescription (Dexedrine®) and is also available on the illicit market. Amphetamines are a class of potent sympathomimetic agents with therapeutic applications. They are chemically related to the human body's natural catecholamines: epinephrine and norepinephrine. Acute higher doses lead to enhanced stimulation of the central nervous system and induce euphoria, alertness, reduced appetite, and a sense of increased energy and power. Cardiovascular responses to Amphetamines include increased blood pressure and cardiac arrhythmias. More acute responses produce anxiety, paranoia, hallucinations, and psychotic behavior. The effects of Amphetamines generally last 2-4 hours following use and the drug has a half-life of 4-24 hours in the body. About 30% of Amphetamines are excreted in the urine in unchanged form, with the remainder as hydroxylated and deaminated derivatives. The One Step Drug Screen Test Card yields a positive result when Amphetamines in urine exceed 1,000 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).⁴

BARBITURATES (BAR)

Barbiturates are central nervous system depressants. They are used therapeutically as sedatives, hypnotics, and anticonvulsants. Barbiturates are almost always taken orally as capsules or tablets. The effects resemble those of intoxication with alcohol. Chronic use of barbiturates leads to tolerance and physical dependence.

Short acting Barbiturates taken at 400 mg/day for 2-3 months can produce a clinically significant degree of physical dependence. Withdrawal symptoms experienced during periods of drug abstinence can be severe enough to cause death.

Only a small amount (less than 5%) of most Barbiturates are excreted unaltered in the urine.

The approximate detection time limits for Barbiturates are:

- Short acting (e.g. 100 mg PO 4.5 days
Secobarbital) (oral)
- Long acting (e.g. 400 mg PO 7 days¹
Phenobarbital) (oral)

The One Step Drug Screen Test Card yields a positive result when the Barbiturates in urine exceed 300 ng/mL.

Drugs of Abuse Screening Test Catalog No. Varies on Configuration (Urine Procedure)

BENZODIAZEPINES (BZO)

Benzodiazepines are medications that are frequently prescribed for the symptomatic treatment of anxiety and sleep disorders. They produce their effects via specific receptors involving a neurochemical called gamma aminobutyric acid (GABA). Because they are safer and more effective, Benzodiazepines have replaced barbiturates in the treatment of both anxiety and insomnia. Benzodiazepines are also used as sedatives before some surgical and medical procedures, and for the treatment of seizure disorders and alcohol withdrawal.

Risk of physical dependence increases if Benzodiazepines are taken regularly (e.g., daily) for more than a few months, especially at higher than normal doses. Stopping abruptly can bring on such symptoms as trouble sleeping, gastrointestinal upset, feeling unwell, loss of appetite, sweating, trembling, weakness, anxiety and changes in perception.

Only trace amounts (less than 1%) of most Benzodiazepines are excreted unaltered in the urine; most of the concentration in urine is conjugated drug. The detection period for the Benzodiazepines in the urine is 3-7 days.

The One Step Drug Screen Test Card yields a positive result when the Benzodiazepines in urine exceed 300 ng/mL.

COCAINE (COC)

Cocaine is a potent central nervous system (CNS) stimulant and a local anesthetic. Initially, it brings about extreme energy and restlessness while gradually resulting in tremors, over-sensitivity and spasms. In large amounts, cocaine causes fever, unresponsiveness, difficulty in breathing and unconsciousness.

Cocaine is often self-administered by nasal inhalation, intravenous injection and free-base smoking. It is excreted in the urine in a short time primarily as Benzoyllecgonine.^{2,3} Benzoyllecgonine, a major metabolite of cocaine, has a longer biological half-life (5-8 hours) than cocaine (0.5-1.5 hours), and can generally be detected for 24-48 hours after cocaine exposure.³

The One Step Drug Screen Test Card yields a positive result when the cocaine metabolite in urine exceeds 300 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).⁴

MARIJUANA (THC)

THC (Δ^9 -tetrahydrocannabinol) is the primary active ingredient in cannabis (marijuana). When smoked or orally administered, THC produces euphoric effects. Users have impaired short term memory and slowed learning. They may also experience transient episodes of confusion and anxiety. Long-term, relatively heavy use may be associated with behavioral disorders. The peak effect of marijuana administered by smoking occurs in 20-30 minutes and the duration is 90-120 minutes after one cigarette. Elevated levels of urinary

Drugs of Abuse Screening Test

Catalog No. Varies on Configuration (Urine Procedure)

metabolites are found within hours of exposure and remain detectable for 3-10 days after smoking. The main metabolite excreted in the urine is 11-nor- Δ^9 -tetrahydrocannabinol-9-carboxylic acid (Δ^9 -THC-COOH).

The One Step Drug Screen Test Card yields a positive result when the concentration of THC-COOH in urine exceeds 50 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).⁴

METHADONE (MTD)

Methadone is a narcotic analgesic prescribed for the management of moderate to severe pain and for the treatment of opiate dependence (heroin, Vicodin, Percocet, Morphine). The pharmacology of Oral Methadone is very different from IV Methadone. Oral Methadone is partially stored in the liver for later use. IV Methadone acts more like heroin. In most states you must go to a pain clinic or a Methadone maintenance clinic to be prescribed Methadone.

Methadone is a long acting pain reliever producing effects that last from twelve to forty-eight hours. Ideally, Methadone frees the client from the pressures of obtaining illegal heroin, from the dangers of injection, and from the emotional roller coaster that most opiates produce. Methadone, if taken for long periods and at large doses, can lead to a very long withdrawal period. The withdrawals from Methadone are more prolonged and troublesome than those provoked by heroin cessation, yet the substitution and phased removal of methadone is an acceptable method of detoxification for patients and therapists.¹

The MTD One Step Methadone Test Card yields a positive result when the Methadone in urine exceeds 300 ng/mL.

METHAMPHETAMINE (mAMP)

Methamphetamine is an addictive stimulant drug that strongly activates certain systems in the brain. Methamphetamine is closely related chemically to amphetamine, but the central nervous system effects of Methamphetamine are greater. Methamphetamine is made in illegal laboratories and has a high potential for abuse and dependence. The drug can be taken orally, injected, or inhaled. Acute higher doses lead to enhanced stimulation of the central nervous system and induce euphoria, alertness, reduced appetite, and a sense of increased energy and power. Cardiovascular responses to Methamphetamine include increased blood pressure and cardiac arrhythmias. More acute responses produce anxiety, paranoia, hallucinations, psychotic behavior, and eventually, depression and exhaustion.

The effects of Methamphetamine generally last 2-4 hours and the drug has a half-life of 9-24 hours in the body. Methamphetamine is excreted in the urine as amphetamine and oxidized and deaminated derivatives. However, 10-20% of Methamphetamine is excreted unchanged. Thus, the presence of the parent compound in the urine indicates Methamphetamine use. Methamphetamine is generally detectable in the urine for 3-5 days, depending on urine pH level.

Drugs of Abuse Screening Test

Catalog No. Varies on Configuration (Urine Procedure)

The One Step Drug Screen Test Card yields a positive result when the Methamphetamine in urine exceeds 1,000 ng/mL.

METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ECSTASY

Methylenedioxymethamphetamine (ecstasy) is a designer drug first synthesized in 1914 by a German drug company for the treatment of obesity.⁸ Those who take the drug frequently report adverse effects, such as increased muscle tension and sweating. MDMA is not clearly a stimulant, although it has, in common with amphetamine drugs, a capacity to increase blood pressure and heart rate. MDMA does produce some perceptual changes in the form of increased sensitivity to light, difficulty in focusing, and blurred vision in some users. Its mechanism of action is thought to be via release of the neurotransmitter serotonin. MDMA may also release dopamine, although the general opinion is that this is a secondary effect of the drug (Nichols and Oberlender, 1990). The most pervasive effect of MDMA, occurring in virtually all people who took a reasonable dose of the drug, was to produce a clenching of the jaws. The One Step Methylenedioxymethamphetamine Drug Screen Test Card yields a positive result when the Methylenedioxymethamphetamine in urine exceeds 500 ng/mL.

OPIATE (MOP 300)

Opiate refers to any drug that is derived from the opium poppy, including the natural products, morphine and codeine, and the semi-synthetic drugs such as heroin. Opioid is more general, referring to any drug that acts on the opioid receptor.

Opioid analgesics comprise a large group of substances which control pain by depressing the central nervous system. Large doses of morphine can produce higher tolerance levels, physiological dependency in users, and may lead to substance abuse. Morphine is excreted unmetabolized, and is also the major metabolic product of codeine and heroin. Morphine is detectable in the urine for several days after an opiate dose.¹

The One Step Drug Screen Test Card yields a positive result when the concentration of opiate exceeds the 300 ng/mL cut-off level.

OPIATE (2000)

The One Step Drug Screen Test Card yields a positive result when the morphine in urine exceeds 2,000 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).⁴ See opiate (MOP 300) for summary.

PHENCYCLIDINE (PCP)

Phencyclidine, also known as PCP or Angel Dust, is a hallucinogen that was first marketed as a surgical anesthetic in the 1950's. It was removed from the market because patients receiving it became delirious and experienced hallucinations.

Drugs of Abuse Screening Test

Catalog No. Varies on Configuration (Urine Procedure)

Phencyclidine is used in powder, capsule, and tablet form. The powder is either snorted or smoked after mixing it with marijuana or vegetable matter. Phencyclidine is most commonly administered by inhalation but can be used intravenously, intra-nasally, and orally. After low doses, the user thinks and acts swiftly and experiences mood swings from euphoria to depression. Self-injurious behavior is one of the devastating effects of Phencyclidine.

PCP can be found in urine within 4 to 6 hours after use and will remain in urine for 7 to 14 days, depending on factors such as metabolic rate, user's age, weight, activity, and diet.⁵ Phencyclidine is excreted in the urine as an unchanged drug (4% to 19%) and conjugated metabolites (25% to 30%).⁶

The One Step Drug Screen Test Card yields a positive result when the phencyclidine level in urine exceeds 25 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).

TRICYCLIC ANTIDEPRESSANTS (TCA)

TCA (Tricyclic Antidepressants) are commonly used for the treatment of depressive disorders. TCA overdoses can result in profound central nervous system depression, cardiotoxicity and anticholinergic effects. TCA overdose is the most common cause of death from prescription drugs. TCAs are taken orally or sometimes by injection. TCAs are metabolized in the liver. Both TCAs and their metabolites are excreted in urine mostly in the form of metabolites for up to ten days.

The One Step Drug Screen Test Card yields a positive result when the concentration of Tricyclic Antidepressants in urine exceeds 1,000 ng/mL.

Drugs of Abuse Screening Test Catalog No. Varies on Configuration (Urine Procedure)

Principle of the Test

The One Step Drug Screen Test Card is an immunoassay based on the principle of competitive binding. Drugs which may be present in the urine specimen compete against their respective drug conjugate for binding sites on their specific antibody.

During testing, a urine specimen migrates upward by capillary action. A drug, if present in the urine specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test line region of the specific drug strip. The presence of drug above the cut-off concentration will saturate all the binding sites of the antibody. Therefore, the colored line will not form in the test line region.

A drug-positive urine specimen will not generate a colored line in the specific test line region of the strip because of drug competition, while a drug-negative urine specimen will generate a line in the test line region because of the absence of drug competition.

To serve as a procedural control, a colored line will always appear at the control line region, indicating that proper volume of specimen has been added and membrane wicking has occurred.

MATERIALS

Reagents and Materials provided

The test contains a membrane strip coated with drug-protein conjugates (purified bovine albumin) on the test line, a goat polyclonal antibody against gold-protein conjugate at the control line, and a dye pad which contains colloidal gold particles coated with mouse monoclonal antibody specific to Amphetamine, Cocaine, Methamphetamine, Methylenedioxymethamphetamine, Morphine, THC, Phencyclidine, Benzodiazepine, Methadone, Barbiturate or Tricyclic Antidepressants.

- Test devices
- Disposable specimen droppers
- Package insert

Materials Required but not Provided

- Specimen collection container
- Timer

Drugs of Abuse Screening Test

Catalog No. Varies on Configuration (Urine Procedure)

Storage and stability

Store as packaged in the sealed pouch at 4-30°C. The test device is stable through the expiration date printed on the sealed pouch. The test device must remain in the sealed pouch until use. **DO NOT FREEZE**. Do not use beyond the expiration date.

Precautions:

- For professional *in vitro* diagnostic use only. Do not use after the expiration date.
- The test device should remain in the sealed pouch until use.
- All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent.
- The test device should be discarded in a proper biohazard container after testing.

Specimen Collection and Preparation

Urine Assay

The urine specimen must be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be centrifuged, filtered, or allowed to settle to obtain a clear specimen for testing.

Specimen Storage

Urine specimens may be stored at 2-8°C for up to 48 hours prior to testing. For prolonged storage, specimens may be frozen and stored below -20°C. Frozen specimens should be thawed and mixed well before testing.


Drugs of Abuse Screening Test
Catalog No. Varies on Configuration (Urine Procedure)

TEST PROCEDURE

Allow the test card, urine specimen, and/or controls to equilibrate to room temperature (15-30°C) prior to testing.

- 1. Bring the pouch to room temperature before opening it. Remove the test card from the sealed pouch and use it as soon as possible. Remove the cap from the end of the test card. With arrows pointing toward the urine specimen, immerse the strip(s) of the test card vertically in the urine specimen for at least 10-15 seconds. Immerse the test card to at least the level of the wavy lines on the strip(s), but not above the arrow(s) on the test card. See the illustration below.*
- 2. Place the test card on a non-absorbent flat surface, start the timer and wait for the red line(s) to appear. The results should be read at 5 minutes. Results remain stable for up to four hours after test initiation.*

Note: This illustration shows a 5-drug test card



Drugs of Abuse Screening Test
Catalog No. Varies on Configuration (Urine Procedure)

INTERPRETATION OF RESULTS

NEGATIVE: * **Two lines appear.** One red line should be in the control region (C), and another apparent red or pink line adjacent should be in the test region (T). This negative result indicates that the drug concentration is below the detectable level.

***NOTE:** The shade of red in the test line region (T) will vary, but it should be considered negative whenever there is even a faint pink line.

POSITIVE: One red line appears in the control region (C). No line appears in the test region (T). This positive result indicates that the drug concentration is above the detectable level.

INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test using a new test panel. If the problem persists, discontinue using the lot immediately and contact your manufacturer.

LIMITATIONS

The One Step Drug Screen Test Card provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method.^{1,4,7}

There is a possibility that technical or procedural errors, as well as other interfering substances in the urine specimen may cause erroneous results.

Adulterants, such as bleach and/or alum, in urine specimens may produce erroneous results regardless of the analytical method used. If adulteration is suspected, the test should be repeated with another urine specimen.

A Positive result does not indicate level or intoxication, administration route or concentration in urine.

A Negative result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the cut-off level of the test.

Test does not distinguish between drugs of abuse and certain medications.

**Drugs of Abuse Screening Test
Catalog No. Varies on Configuration (Urine Procedure)**

QUALITY CONTROL

A procedural control is included in the test. A red line appearing in the control region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique. Control standards are not supplied with this kit. However, it is recommended that positive and negative controls be tested as good laboratory practice to confirm the test procedure and to verify proper test performance.

Technical Service Representative

For technical assistance contact:

**Instant Technologies, Inc.
880 Norfolk Square
Norfolk, VA
Phone: (800) 340-4029
Fax: (888) 340-4029**

**Drugs of Abuse Screening Test
Catalog No. Varies on Configuration (Urine Procedure)**

PERFORMANCE CHARACTERISTICS

Accuracy

A side-by-side comparison was conducted using the One Step Single Drug Test Strip and commercially available drug rapid tests. Testing was performed on approximately 300 specimens per drug type previously collected from subjects presenting for Drug Screen Testing. Presumptive positive results were confirmed by GC/MS. The following compounds were quantified by GC/MS and contributed to the total amount of drugs found in presumptive positive urine samples tested.

| Test | Compounds Contributed to the Totals of GC/MS |
|------|--|
| AMP | Amphetamine |
| BAR | Secobarbital, Butalbital, Phenobarbital, Pentobarbital |
| BZO | Oxazepam, Nordiazepam, OH-Alprazolam, Desalkylflurazepam |
| COC | Benzoyllecgonine |
| THC | 11-nor- Δ^9 -tetrahydrocannabinol-9-carboxylic acid |
| MTD | Methadone |
| mAMP | Methamphetamine |
| MDMA | D,L Methyleneoxyamphetamine |
| OPI | Morphine, Codeine |
| PCP | Phencyclidine |
| TCA | Nortriptyline |

The following results are tabulated from these clinical studies:

| Method | | GC/MS | | | | | |
|--|----------|-------|--------------------------------|--|---|--------------------------------|-----------------------------------|
| Multi-Drug Single-Line Test Card | | Neg. | Neg. ($< -25\%$ cutoff) | Near cutoff neg. (-25% cutoff to cutoff) | Near cutoff pos. (cutoff to $+25\%$ cutoff) | Pos. ($> +25\%$ cutoff) | % agree- ment with GC/MS |
| AMP | Positive | 0 | 1 | 8 | 18 | 114 | 97% |
| | Negative | 149 | 1 | 5 | 4 | 0 | 95% |
| BAR | Positive | 0 | 0 | 4 | 5 | 117 | 92% |
| | Negative | 150 | 1 | 5 | 1 | 9 | 98% |
| BZO | Positive | 0 | 7 | 1 | 5 | 26 | 97% |
| | Negative | 149 | 7 | 1 | 3 | 1 | 95% |
| COC | Positive | 0 | 2 | 15 | 16 | 103 | 96% |
| | Negative | 150 | 5 | 7 | 1 | 1 | 90% |
| THC | Positive | 0 | 13 | 9 | 12 | 109 | 96% |
| | Negative | 150 | 6 | 0 | 0 | 1 | 97% |
| MTD | Positive | 0 | 0 | 10 | 10 | 112 | 99% |
| | Negative | 150 | 17 | 0 | 0 | 1 | 94% |
| mAMP | Positive | 0 | 0 | 10 | 9 | 126 | 99% |

Drugs of Abuse Screening Test Catalog No. Varies on Configuration (Urine Procedure)

| | | | | | | | |
|------|----------|-----|----|----|----|-----|------|
| | Negative | 150 | 0 | 4 | 1 | 0 | 94% |
| MDMA | Positive | 0 | 0 | 3 | 6 | 82 | 98% |
| | Negative | 147 | 0 | 2 | 0 | 0 | >99% |
| MOP | Positive | 0 | 2 | 7 | 10 | 131 | >99% |
| | Negative | 150 | 0 | 0 | 0 | 0 | 94% |
| OPI | Positive | 0 | 0 | 16 | 18 | 116 | >99% |
| | Negative | 150 | 0 | 0 | 0 | 0 | 90% |
| PCP | Positive | 0 | 0 | 6 | 10 | 40 | >99% |
| | Negative | 150 | 6 | 0 | 0 | 0 | 97% |
| *TCA | Positive | 0 | 12 | 8 | 15 | 20 | >99% |
| | Negative | 150 | 17 | 0 | 0 | 0 | 89% |

%Agreement with Commercial Kit

| | AMP | BAR | BZO | COC | THC | MTD |
|--------------------|------|------|-----|------|------|------|
| Positive Agreement | 97% | >99% | 90% | 95% | 98% | 99% |
| Negative Agreement | 100% | >99% | 97% | >99% | 100% | >99% |
| Total Results | 98% | 99% | 94% | 98% | 99% | >99% |

| | mAMP | MDMA | MOP | OPI | PCP | TCA |
|--------------------|------|------|------|------|------|------|
| Positive Agreement | 98% | 100% | 100% | >99% | 98% | 95% |
| Negative Agreement | 100% | 99% | 100% | >99% | 100% | >99% |
| Total Results | 99% | 99% | 100% | >99% | 99% | 99% |

%Agreement with GC/MS

| | AMP | BAR | BZO | COC | THC | MTD |
|--------------------|-----|-----|-----|-----|-----|------|
| Positive Agreement | 97% | 92% | 97% | 96% | 96% | 99% |
| Negative Agreement | 95% | 98% | 95% | 90% | 97% | >94% |
| Total Results | 96% | 95% | 96% | 93% | 96% | >96% |

| | mAMP | MDMA | MOP | OPI | PCP | TCA* |
|--------------------|------|------|------|------|------|------|
| Positive Agreement | 99% | 98% | 100% | >99% | 100% | >99% |
| Negative Agreement | 94% | >99% | 94% | >90% | 97% | 89% |
| Total Results | 96% | 99% | 97% | >95% | 98% | 91% |

Forty (40) clinical samples for each drug were run using each of The One Step Single Drug Test Strip by an untrained operator at a Professional Point of Care site. Based on GC/MS data, the operator obtained statistically similar Positive Agreement, Negative Agreement and Overall Agreement rates as trained laboratory personnel.

*Note: TCA was based on HPLC data.

Drugs of Abuse Screening Test

Catalog No. Varies on Configuration (Urine Procedure)

Precision

A study was conducted at three physician offices by untrained operators using three different lots of product to demonstrate the within run, between run and between operator precision. An identical panel of coded specimens, containing drugs at the concentration of $\pm 50\%$ and $\pm 25\%$ cut-off level, was labeled, blinded and tested at each site. The results are given below:

AMPHETAMINE (AMP)

| Amphetamine conc. (ng/mL) | n per site | Site A | | Site B | | Site C | |
|---------------------------|------------|--------|----|--------|----|--------|----|
| | | - | + | - | + | - | + |
| 0 | 15 | 15 | 0 | 15 | 0 | 15 | 0 |
| 500 | 15 | 15 | 0 | 15 | 0 | 14 | 1 |
| 750 | 15 | 13 | 2 | 11 | 4 | 11 | 4 |
| 1,250 | 15 | 6 | 9 | 4 | 11 | 4 | 11 |
| 1,500 | 15 | 2 | 13 | 1 | 14 | 1 | 14 |

BARBITURATES (BAR)

| Secobarbital conc. (ng/mL) | n per site | Site A | | Site B | | Site C | |
|----------------------------|------------|--------|----|--------|----|--------|----|
| | | - | + | - | + | - | + |
| 0 | 15 | 15 | 0 | 15 | 0 | 15 | 0 |
| 150 | 15 | 13 | 2 | 15 | 0 | 15 | 0 |
| 225 | 15 | 5 | 10 | 7 | 8 | 10 | 5 |
| 375 | 15 | 2 | 13 | 5 | 10 | 5 | 10 |
| 450 | 15 | 0 | 15 | 1 | 14 | 1 | 14 |

BENZODIAZEPINES (BZO)

| Oxazepam conc. (ng/mL) | n per site | Site A | | Site B | | Site C | |
|------------------------|------------|--------|----|--------|----|--------|----|
| | | - | + | - | + | - | + |
| 0 | 15 | 15 | 0 | 15 | 0 | 15 | 0 |
| 150 | 15 | 14 | 1 | 14 | 1 | 15 | 0 |
| 225 | 15 | 11 | 4 | 14 | 1 | 14 | 1 |
| 375 | 15 | 0 | 15 | 1 | 14 | 3 | 12 |
| 450 | 15 | 0 | 15 | 0 | 15 | 0 | 15 |

COCAINE (COC)

| Benzoyllecgonine | n per site | Site A | Site B | Site C |
|------------------|------------|--------|--------|--------|
|------------------|------------|--------|--------|--------|

Drugs of Abuse Screening Test Catalog No. Varies on Configuration (Urine Procedure)

| conc. (ng/mL) | site | - | + | - | + | - | + |
|---------------|------|-----|--------|--------|--------|--------|----|
| 0 | 15 | 14* | 0 | 1 5 | 0 | 1 5 | 0 |
| 150 | 15 | 14 | 1 | 1 5 | 0 | 1 4 | 1 |
| 225 | 15 | 4 | 1 1 | 5 | 1 0 | 8 | 7 |
| 375 | 15 | 0 | 1 5 | 0 | 1 5 | 0 | 15 |
| 450 | 15 | 0 | 1 5 | 0 | 1 5 | 1 | 14 |

*Note: One invalid result was obtained.

MARIJUANA (THC)

| 11-nor- Δ^9 -THC-9-COOH conc. (ng/mL) | n per site | Site A | | Site B | | Site C | |
|--|------------|--------|--------|--------|--------|--------|----|
| | | - | + | - | + | - | + |
| 0 | 15 | 15 | 0 | 1 5 | 0 | 1 5 | 0 |
| 25 | 15 | 15 | 0 | 1 5 | 0 | 1 4 | 1 |
| 37.5 | 15 | 9 | 6 | 1 4 | 1 | 9 | 6 |
| 62.5 | 15 | 2 | 1 3 | 0 | 1 5 | 0 | 15 |
| 75 | 15 | 0 | 1 5 | 0 | 1 5 | 0 | 15 |

METHADONE (MTD)

| Methadone conc. (ng/mL) | n per site | Site A | | Site B | | Site C | |
|-------------------------|------------|--------|--------|--------|--------|--------|----|
| | | - | + | - | + | - | + |
| 0 | 15 | 1 5 | 0 | 1 5 | 0 | 1 5 | 0 |
| 150 | 15 | 1 2 | 3 | 1 5 | 0 | 1 5 | 0 |
| 225 | 15 | 8 | 7 | 1 4 | 1 | 1 5 | 0 |
| 375 | 15 | 0 | 1 5 | 0 | 1 5 | 1 | 14 |
| 450 | 15 | 1 | 1 4 | 0 | 1 5 | 0 | 15 |

METHAMPHETAMINE (mAMP)

| Methamphetamine conc. (ng/mL) | n per site | Site A | | Site B | | Site C | |
|-------------------------------|------------|--------|--------|--------|--------|--------|----|
| | | - | + | - | + | - | + |
| 0 | 15 | 15 | 0 | 1 5 | 0 | 1 5 | 0 |
| 500 | 15 | 15 | 0 | 1 4 | 1 | 1 3 | 2 |
| 750 | 15 | 11 | 4 | 1 0 | 5 | 1 0 | 5 |
| 1,250 | 15 | 8 | 7 | 4 | 1 1 | 6 | 9 |
| 1,500 | 15 | 1 | 1 4 | 1 | 1 4 | 0 | 15 |

Drugs of Abuse Screening Test

Catalog No. Varies on Configuration (Urine Procedure)

METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ECSTASY

| Methylenedioxy-methamphetamine conc. (ng/mL) | n per site | Site A | | Site B | | Site C | |
|--|------------|--------|--------|--------|--------|--------|----|
| | | - | + | - | + | - | + |
| 0 | 15 | 15 | 0 | 1 5 | 0 | 1 5 | 0 |
| 250 | 15 | 15 | 0 | 1 5 | 0 | 1 5 | 0 |
| 375 | 15 | 15 | 0 | 1 5 | 0 | 1 5 | 0 |
| 625 | 15 | 6 | 9 | 4 | 1 1 | 7 | 8 |
| 750 | 15 | 0 | 1 5 | 0 | 1 5 | 0 | 15 |

OPIATE (MOP 300)

| Morphine conc. (ng/mL) | n per site | Site A | | Site B | | Site C | |
|------------------------|------------|--------|--------|--------|--------|--------|----|
| | | - | + | - | + | - | + |
| 0 | 15 | 1 5 | 0 | 1 5 | 0 | 1 5 | 0 |
| 150 | 15 | 1 3 | 2 | 1 3 | 2 | 1 5 | 0 |
| 225 | 15 | 3 | 1 2 | 7 | 8 | 1 0 | 5 |
| 375 | 15 | 0 | 1 5 | 1 | 1 4 | 0 | 15 |
| 450 | 15 | 0 | 1 5 | 0 | 1 5 | 0 | 15 |

OPIATES (OPI 2000)

| Morphine conc. (ng/mL) | n per site | Site A | | Site B | | Site C | |
|------------------------|------------|--------|--------|--------|--------|--------|----|
| | | - | + | - | + | - | + |
| 0 | 15 | 1 5 | 0 | 1 5 | 0 | 1 5 | 0 |
| 1,000 | 15 | 1 5 | 0 | 1 5 | 0 | 1 4 | 1 |
| 1,500 | 15 | 1 3 | 2 | 1 1 | 4 | 7 | 8 |
| 2,500 | 15 | 4 | 1 1 | 1 | 1 4 | 2 | 13 |
| 3,000 | 15 | 0 | 1 5 | 0 | 1 5 | 2 | 13 |

PHENCYCLIDINE (PCP)

| Phencyclidine conc. (ng/mL) | n per site | Site A | | Site B | | Site C | |
|-----------------------------|------------|--------|--------|--------|--------|--------|----|
| | | - | + | - | + | - | + |
| 0 | 15 | 1 5 | 0 | 1 5 | 0 | 1 5 | 0 |
| 12.5 | 15 | 1 5 | 0 | 1 4 | 1 | 1 4 | 1 |
| 18.75 | 15 | 1 1 | 4 | 1 3 | 2 | 1 0 | 5 |
| 31.25 | 15 | 8 | 7 | 5 | 1 0 | 1 | 14 |
| 37.5 | 15 | 4 | 1 1 | 0 | 1 5 | 0 | 15 |

Drugs of Abuse Screening Test

Catalog No. Varies on Configuration (Urine Procedure)

TRICYCLIC ANTIDEPRESSANTS (TCA)

| Nortriptyline conc. (ng/mL) | n per site | Site A | | Site B | | Site C | |
|--------------------------------|---------------|--------|--------|--------|--------|--------|----|
| | | - | + | - | + | - | + |
| 0 | 15 | 1 5 | 0 | 1 5 | 0 | 1 5 | 0 |
| 500 | 15 | 1 5 | 0 | 1 5 | 0 | 1 5 | 0 |
| 750 | 15 | 1 4 | 1 | 1 1 | 4 | 1 4 | 1 |
| 1,250 | 15 | 8 | 7 | 2 | 1 3 | 6 | 9 |
| 1,500 | 15 | 1 | 1 4 | 0 | 1 5 | 1 | 14 |

Analytical Sensitivity

A drug-free urine pool was spiked with drugs at concentrations listed. The results are summarized below.

| Drug concentration Cut-off Range | n | AMP | | BAR | | BZO | | COC | |
|-------------------------------------|----|-----|----|-----|----|-----|----|-----|----|
| | | - | + | - | + | - | + | - | + |
| 0% Cut-off | 30 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -50% Cut-off | 30 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -25% Cut-off | 30 | 22 | 8 | 27 | 3 | 26 | 4 | 30 | 0 |
| Cut-off | 30 | 12 | 18 | 22 | 8 | 12 | 18 | 4 | 26 |
| +25% Cut-off | 30 | 2 | 28 | 7 | 23 | 3 | 27 | 0 | 30 |
| +50% Cut-off | 30 | 0 | 30 | 2 | 28 | 0 | 30 | 0 | 30 |

| Drug Concentration Cut-off Range | n | THC | | MTD | | mAMP | | MDMA | |
|-------------------------------------|----|-----|----|-----|----|------|----|------|----|
| | | - | + | - | + | - | + | - | + |
| 0% Cut-off | 30 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -50% Cut-off | 30 | 30 | 0 | 29 | 1 | 30 | 0 | 30 | 0 |
| -25% Cut-off | 30 | 12 | 18 | 24 | 6 | 30 | 0 | 26 | 4 |
| Cut-off | 30 | 1 | 29 | 21 | 9 | 18 | 12 | 17 | 13 |
| +25% Cut-off | 30 | 1 | 29 | 2 | 28 | 1 | 29 | 4 | 26 |
| +50% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |

| Drug Concentration Cut-off Range | n | MOP | | OPI | | PCP | | TCA | |
|-------------------------------------|----|-----|----|-----|----|-----|----|-----|----|
| | | - | + | - | + | - | + | - | + |
| 0% Cut-off | 30 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -50% Cut-off | 30 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 |
| -25% Cut-off | 30 | 25 | 5 | 30 | 0 | 19 | 11 | 22 | 8 |
| Cut-off | 30 | 17 | 13 | 13 | 17 | 16 | 14 | 12 | 18 |
| +25% Cut-off | 30 | 1 | 29 | 4 | 20 | 6 | 24 | 7 | 23 |
| +50% Cut-off | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 |

Drugs of Abuse Screening Test Catalog No. Varies on Configuration (Urine Procedure)

Analytical Specificity

The following table lists the concentration of compounds (ng/mL) that are detected positive in urine by One Step Drug Screen Test Card at 5 minutes.

| | |
|-----------------------------------|--------|
| AMPHETAMINE | ng/mL |
| D-Amphetamine | 1,000 |
| D,L-Amphetamine sulfate | 3,000 |
| L-Amphetamine | 50,000 |
| (±)3,4-Methylenedioxyamphetamine | 2,000 |
| Phentermine | 3,000 |
| BARBITURATES | |
| Secobarbital | 300 |
| Amobarbital | 300 |
| Alphenol | 150 |
| Aprobarbital | 200 |
| Butabarbital | 75 |
| Butalbital | 2,500 |
| Butethal | 100 |
| Cyclopentobarbital | 600 |
| Pentobarbital | 300 |
| Phenobarbital | 100 |
| BENZODIAZEPINES | |
| Oxazepam | 300 |
| Alprazolam | 196 |
| Hydroxyalprazolam | 1,262 |
| Bromazepam | 1,562 |
| Chlordiazepoxide | 1,562 |
| Chlordiazepoxide HCl | 781 |
| Clobazam | 98 |
| Clonazepam | 781 |
| Clorazepate dipotassium | 195 |
| Delorazepam | 1,562 |
| Desalkylflurazepam | 390 |
| Diazepam | 195 |
| Estazolam | 2,500 |
| Flunitrazepam | 390 |
| (±) Lorazepam | 1,562 |
| RS-Lorazepam glucuronide | 156 |
| Midazolam | 12,500 |
| Nitrazepam | 98 |
| Norchlordiazepoxide | 195 |
| Nordiazepam | 390 |
| Temazepam | 98 |
| Triazolam | 2,500 |
| COCAINE | |
| Benzoylcegonine | 300 |
| Cocaine HCl | 780 |
| Cocaethylene | 12,500 |
| Ecgonine HCl | 32,000 |
| MARIJUANA (THC) | |
| 11-nor- Δ^9 -THC-9 COOH | 50 |
| Cannabinol | 20,000 |
| 11-nor- Δ^8 -THC-9 COOH | 30 |
| Δ^8 -THC | 15,000 |
| Δ^9 -THC | 15,000 |
| METHADONE | |
| Methadone | 300 |
| Doxylamine | 50,000 |
| METHAMPHETAMINE | |
| D-Methamphetamine | 1,000 |
| ρ -Hydroxymethamphetamine | 30,000 |
| L-Methamphetamine | 8,000 |
| (±)-3,4-Methylenedioxyamphetamine | 2,000 |
| Mephentermine | 50,000 |

Drugs of Abuse Screening Test Catalog No. Varies on Configuration (Urine Procedure)

| | |
|--|---------|
| METHYLENEDIOXYMETHAMPHETAMINE (MDMA) | ng/mL |
| D,L-3,4-Methylenedioxyamphetamine HCl (MDMA) | 500 |
| 3,4-Methylenedioxyamphetamine HCl (MDA) | 3,000 |
| 3,4-Methylenedioxyethylamphetamine (MDEA) | 300 |
| OPIATE (MOP 300) | |
| Morphine | 300 |
| Codeine | 300 |
| Ethylmorphine | 6,250 |
| Hydrocodone | 50,000 |
| Hydromorphone | 3,125 |
| Levorphanol | 1500 |
| 6-Monoacetylmorphine | 400 |
| Morphine 3-β-D-glucuronide | 1,000 |
| Norcodeine | 6,250 |
| Normorphine | 100,000 |
| Oxycodone | 30,000 |
| Oxymorphone | 100,000 |
| Procaine | 15,000 |
| Thebaine | 6,250 |
| OPIATES (2000) | |
| Morphine | 2,000 |
| Codeine | 2,000 |
| Ethylmorphine | 5,000 |
| Hydrocodone | 12,500 |
| Hydromorphone | 5,000 |
| Levorphanol | 75,000 |
| 6-Monoacetylmorphine | 5,000 |
| Morphine 3-β-D-glucuronide | 2,000 |
| Norcodeine | 12,500 |
| Normorphine | 50,000 |
| Oxycodone | 25,000 |
| Oxymorphone | 25,000 |
| Procaine | 150,000 |
| Thebaine | 100,000 |
| PCP | |
| Phencyclidine | 25 |
| 4-Hydroxyphencyclidine | 12,500 |
| TCA | |
| Notriptyline | 1,000 |
| Nordoxepin | 1,000 |
| Trimipramine | 3,000 |
| Amitriptyline | 1,500 |
| Promazine | 1,500 |
| Desipramine | 200 |
| Imipramine | 400 |
| Clomipramine | 12,500 |
| Doxepin | 2,000 |
| Maprotiline | 2,000 |
| Promethazine | 25,000 |

Effect of Urinary Specific Gravity

Fifteen (15) urine samples of normal, high, and low specific gravity ranges (1.000-1.037) were spiked with drugs at 50% below and 50% above cut-off levels respectively. The One Step Drug Screen Test Card was tested in duplicate using fifteen drug-free urine and spiked urine samples. The results demonstrate that varying ranges of urinary specific gravity does not affect the test results.

Effect of the Urinary pH

The pH of an aliquoted negative urine pool was adjusted to a pH range of 5 to 9 in 1 pH unit increments and spiked with drugs at 50% below and 50% above cut-off levels. The spiked, pH-adjusted urine was tested with One Step Drug Screen Test Card. The results demonstrate that varying ranges of pH does not interfere with the performance of the test.

Drugs of Abuse Screening Test

Catalog No. Varies on Configuration (Urine Procedure)

Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-free urine or drug positive urine containing, Amphetamine, Barbiturates, Benzodiazepines, Cocaine, Marijuana, Methadone, Methamphetamine, Methylenedioxymethamphetamine, Opiate, Phencyclidine or Tricyclic Antidepressants. The following compounds show no cross-reactivity when tested with One Step Drug Screen Test Card at a concentration of 100 µg/mL.

Non Cross-Reacting Compounds

| | |
|---|---|
| Acetaminophen | Acetophenetidin |
| N-Acetylprocainamide | Acetylsalicylic acid |
| Aminopyrine | Amoxicillin |
| Ampicillin | L-Ascorbic acid |
| Apomorphine | Aspartame |
| Atropine | Benzilic acid |
| Benzoic acid | Benzphetamine* |
| Bilirubin | D/L-Brompheniramine |
| Caffeine | Cannabidiol |
| Chloralhydrate | Chloramphenicol |
| Chlorothiazide | D/L-Chloropheniramine |
| Chlorpromazine | Chloroquine |
| Cholesterol | Clonidine |
| Cortisone | L-Cotinine |
| Creatinine | Deoxycorticosterone |
| Dextromethorphan | Diclofenac |
| Diflunisal | Digoxin |
| Diphenhydramine | Ecgonine methyl ester |
| L -_-Ephedrine | β-Estradiol |
| Estrone-3-sulfate | Ethyl-p-aminobenzoate |
| [1R,2S] (-) Ephedrine | L(-)-Epinephrine |
| Erythromycin | Fenoprofen |
| Furosemide | Gentisic acid |
| Hemoglobin | Hydralazine |
| Hydrochlorothiazide | Hydrocortisone |
| O-Hydroxyhippuric acid | p-Hydroxyamphetamine |
| p-Hydroxytyramine | Ibuprofen |
| Iproniazid | D/L-Isoproterenol |
| Isoxsuprine | Ketamine |
| Ketoprofen | Labetalol |
| Loperamide | Meperidine |
| Meprobamate | Methoxyphenamine |
| Methylphenidate | Nalidixic acid |
| Naloxone | Naltrexone |
| Naproxen | Niacinamide |
| Nifedipine | Norethindrone |
| D-Norpropoxyphene | Noscapine |
| D/L-Octopamine | Oxalic acid |
| Oxolinic acid | Oxymetazoline |
| Papaverine | Penicillin-G |
| Pentazocine hydrochloride | Perphenazine |
| Phenelzine | Trans-2-phenylcyclo-propylamine hydrochloride |
| L-Phenylephrine | β-Phenylethylamine |
| Phenylpropanolamine | Prednisolone |
| Prednisone | D/L-Propranolol |
| D-Propoxyphene | D-Pseudoephedrine |
| Quinacrine | Quinine |
| Quindine | Rantidine |
| Salicylic acid | Serotonin |
| Sulfamethazine | Sulindac |
| Tetracycline | Tetrahydrocortisone 3-acetate |
| Tetrahydrocortisone 3 (β-D-glucuronide) | Tetrahydrozoline |
| Thiamine | Thioridazine |
| D/L-Tyrosine | Tolbutamide |
| Triamterene | Trifluoperazine |
| Trimethoprim | Tryptamine |
| D/L-Tryptophan | Tyramine |
| Uric acid | Verapamil |

Drugs of Abuse Screening Test

Catalog No. Varies on Configuration (Urine Procedure)

Zomepirac

BIBLIOGRAPHY

1. Tietz NW. *Textbook of Clinical Chemistry*. W.B. Saunders Company. 1986; 1735.
2. Stewart DJ, Inaba T, Lucassen M, Kalow W. *Clin. Pharmacol. Ther.* April 1979; 25 ed: 464, 264-8.
3. Ambre J. *J. Anal. Toxicol.* 1985; 9:241.
4. Hawks RL, CN Chiang. *Urine Testing for Drugs of Abuse*. National Institute for Drug Abuse (NIDA), Research Monograph 73, 1986.
5. FDA Guidance Document: Guidance for Premarket Submission for Kits for Screening Drugs of Abuse to be Used by the Consumer, 1997.
6. Robert DeCresce. *Drug Testing in the workplace*, 114.
7. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 2nd Ed. Biomedical Publ., Davis, CA 1982; 487.
8. Winger, Gail, *A Handbook of Drug and Alcohol Abuse*, Third Edition, Oxford Press, 1992, page 146.



Brought to You by Employee Drug Testing Ace

Buying discounted, accurate, high quality employment drug testing kits and services is affordable, fast, easy, safe and secure with **Employee Drug Testing Ace**. You can buy employment, pre-employment and employee drug and alcohol testing kits, services and supplies tailored for employers, TPAs, nursing homes, hospitals, manufacturing, moving companies, Department of Transportation DOT, local and Federal Government agencies, auto dealerships, construction, DOD, the work place, employment agencies and more.

Our easy to use [employee drug testing](#) kits are DOT Approved, CLIA Waived, FDA 510k Cleared and SAMHSA Compliant. We provide both onsite employment drug screening and offsite employee drug screening services along with SAMHSA certified confirmation and medical review officer (MRO) services. All [employment drug screening](#) kits are on sale, discounted, and have [bulk / volume discounts](#).

- **Pay No Taxes in the USA.**, except California.
- **100% Free UPS Standard Shipping** in the Continental U.S.A. for *All* Products.
- **100% Free FedEx Overnight Shipping** in the Continental U.S.A. for *All* Specimens sent in as part of our SAMHSA Certified Confirmation Drug Testing Service.
- Onsite Third Party Administered (TPA) Employee Drug and Alcohol Collection Services.
- Over 12,000 Offsite Employee Drug and Alcohol Testing Locations Nationwide.
- The most complete [Employment Drug Testing Resource Center](#) including: information, official documents, work place drug testing information, forms, work accident info, charts, videos, post accident drug testing info, training materials, contact lists, definitions and more!

We sell affordable and guaranteed [employee drug screening](#) kits and services available at the best prices. Our prices may be cheap but our drug testing kits are of the highest quality and accuracy. If you are in the market for discounted high quality pre-employment, employee, or [employment drug testing](#) and screening kits and services, visit us today. You will be happy you did!